- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05), with no kidney-related adverse events observed in these post-hoc analyses
-Treatment with acoramidis provided a sustained, improved chronic eGFR slope (+2.47 mL/min/1.73m²/year; p<0.001) sustained UACR reduction (13.7%; p=0.026) through Month 30
- Acoramidis demonstrated a profile consistent with drugs that act directly on the kidney, such as ACE inhibitors, ARBs, and SGLT2 inhibitors, which has not previously been observed with any other approved ATTR-CM therapy and supports a direct kidney mechanism that is potentially independent of TTR-stabilization
-The magnitude of the acute eGFR dip in participants treated with acoramidis was positively associated with a reduction in early cardiovascular outcomes; the opposite was observed with placebo